- United States
- /
- Medical Equipment
- /
- NasdaqCM:BEAT
Insider Buyers Lose US$8.5k As HeartBeam Sheds US$6.4m
The recent price decline of 11% in HeartBeam, Inc.'s (NASDAQ:BEAT) stock may have disappointed insiders who bought US$80.0k worth of shares at an average price of US$1.70 in the past 12 months. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$71.5k, which is not great.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
HeartBeam Insider Transactions Over The Last Year
The Executive Chairman Richard Ferrari made the biggest insider purchase in the last 12 months. That single transaction was for US$50k worth of shares at a price of US$1.70 each. That means that even when the share price was higher than US$1.52 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
Over the last year, we can see that insiders have bought 47.06k shares worth US$80k. On the other hand they divested 12.17k shares, for US$28k. Overall, HeartBeam insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
View our latest analysis for HeartBeam
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Insider Ownership Of HeartBeam
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that HeartBeam insiders own 20% of the company, worth about US$10m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Do The HeartBeam Insider Transactions Indicate?
The fact that there have been no HeartBeam insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Overall we don't see anything to make us think HeartBeam insiders are doubting the company, and they do own shares. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 5 warning signs we've spotted with HeartBeam (including 3 which make us uncomfortable).
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we're here to simplify it.
Discover if HeartBeam might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:BEAT
HeartBeam
Operates as a medical technology company that focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting.
Medium-low risk with mediocre balance sheet.
Similar Companies
Market Insights
Weekly Picks

Is this the AI replacing marketing professionals?
Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business
The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery Â
The Infrastructure AI Cannot Be Built Without
Recently Updated Narratives

Kratos Defense & Security Solutions (KTOS): Scaling "Attritable" Dominance in a New Era of Aerial Conflict.

BWX Technologies (BWXT): Powering the Nuclear Renaissance from Naval Depths to Medical Frontiers.

Merck & Co. (MRK): Scaling the "Post-Keytruda Hill" Through Diversified Blockbusters.
Popular Narratives
Nu holdings will continue to disrupt the South American banking market

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
